As many as one in six clinically recognised pregnancies miscarry, and many women suffer the loss of three or more consecutive babies without any apparent reason for such recurrent miscarriage. The economic, societal and psychological costs are tremendous. The PROMISE trial tests whether treatment with progesterone (a natural pregnancy hormone) in the first trimester can reduce the risk of miscarriage in women with a previous history of unexplained recurrent loss. The study is taking place in approximately 50 hospitals across the UK and the Netherlands.
|Short title||The Immunological Consequences of First Trimester Progesterone Treatment in Recurrent Miscarriage (PROMISE PLUS)|
|Effective start/end date||4/07/11 → 30/09/15|
- BIRMINGHAM WOMENS NHS TRUST
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.